S.D. Fosså
Impact in
- Reproductive Medicine top 2%
- Ovarian cancer diagnosis and treatment
- Surgery top 5%
- Testicular diseases and treatments
Papers in
-
- Ovarian cancer diagnosis and treatment 7
- Surgery 43
- Testicular diseases and treatments 32
- Bladder and Urothelial Cancer Treatments 7
S.D. Fosså
69 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 94
- Reproductive Medicine 359
- Surgery 1.1k
- Pulmonary and Respiratory Medicine 607
- Oncology 454
- Rheumatology 231
Countries citing papers authored by S.D. Fosså
This map shows the geographic impact of S.D. Fosså's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.D. Fosså with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.D. Fosså more than expected).
Fields of papers citing papers by S.D. Fosså
This network shows the impact of papers produced by S.D. Fosså. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.D. Fosså. The network helps show where S.D. Fosså may publish in the future.
Co-authorship network
The 25 scholars most cited alongside S.D. Fosså, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 30 | |
| 2 | 2009 | 38 | |
| 3 | 2002 | 78 | |
| 4 | Is 3BEP equivalent to 3BEP+1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study | 1999 | 3 |
| 5 | Adjuvant bleomycin, vincristine and cisplatin (BOP) for high risk clinical stage I (HRCS 1) non-seminomatous germ cell tumours (NSGCT) - a Medical Research Council (MRC) pilot study. | 1998 | 12 |
| 6 | 1997 | 50 | |
| 7 | 1997 | 14 | |
| 8 | 1997 | 14 | |
| 9 | 1997 | 12 | |
| 10 | Optimal field size in adjuvant radiotherapy (XRT) of stage I seminoma - a randomised trial | 1996 | 8 |
| 11 | Resection of residual retroperitoneal masses in testicular cancer | 1996 | 2 |
| 12 | 1996 | 24 | |
| 13 | 1996 | 11 | |
| 14 | 1996 | 36 | |
| 15 | 1995 | 1 | |
| 16 | 1995 | 28 | |
| 17 | 1994 | 31 | |
| 18 | 1993 | 38 | |
| 19 | Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis - preliminary report of an MRC study | 1992 | 4 |
| 20 | 1992 | 6 |
About S.D. Fosså
S.D. Fosså is a scholar working on Reproductive Medicine, Surgery, Pulmonary and Respiratory Medicine, Oncology and Rheumatology, having authored 71 papers that have together received 1.9k indexed citations. Recurring topics across this work include Testicular diseases and treatments (32 papers), Prostate Cancer Treatment and Research (15 papers), Urologic and reproductive health conditions (9 papers), Prostate Cancer Diagnosis and Treatment (8 papers), Bladder and Urothelial Cancer Treatments (7 papers), Ovarian cancer diagnosis and treatment (7 papers), Neuroblastoma Research and Treatments (6 papers) and Renal cell carcinoma treatment (5 papers). The work is most often cited by research in Reproductive Medicine (359 citations), Surgery (1.1k citations), Pulmonary and Respiratory Medicine (607 citations), Oncology (454 citations) and Rheumatology (231 citations). S.D. Fosså has collaborated with scholars based in Norway, United Kingdom and Netherlands. Frequent co-authors include Steinar Tretli, Nina Aass, A. Gerl, Sally Stenning, S. Ous, A. Horwich, Ketil Heimdal, J. Beyer, Olbjørn Klepp and Eva Hoff Wanderås. Their work appears in journals such as British Journal of Cancer, European Journal of Cancer, Journal of Clinical Oncology, European Urology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.